Published in Clin Cancer Res on August 01, 2008
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02
Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer (2009) 1.48
Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res (2011) 1.40
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30
Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest (2011) 1.28
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther (2012) 1.16
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res (2011) 1.16
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol (2012) 1.09
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res (2012) 1.04
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res (2009) 1.03
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs (2010) 0.99
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer (2014) 0.99
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res (2009) 0.97
Innovative therapeutic strategies in the treatment of brain metastases. Int J Mol Sci (2013) 0.94
Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. PLoS One (2011) 0.94
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs (2009) 0.93
The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am (2009) 0.92
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res (2014) 0.90
Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep (2012) 0.89
Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am (2011) 0.89
Molecular markers of tumor progression in melanoma. Curr Genomics (2009) 0.88
Targeting oncogenic BRAF in human cancer. Curr Top Microbiol Immunol (2012) 0.86
Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am (2014) 0.85
Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol (2011) 0.84
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PLoS One (2011) 0.83
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. J Skin Cancer (2011) 0.82
Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clin Exp Metastasis (2012) 0.81
BRAF inhibitor unveils its potential against advanced melanoma. Cancer Cell (2010) 0.81
Sorafenib in advanced melanoma: a critical role for pharmacokinetics? Br J Cancer (2012) 0.81
Parsing out the complexity of RAF inhibitor resistance. Pigment Cell Melanoma Res (2011) 0.81
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma. J Immunother (2014) 0.80
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res (2015) 0.80
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer (2011) 0.80
The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharm Sin B (2014) 0.79
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One (2013) 0.78
New treatment approaches in melanoma: current research and clinical prospects. Ther Adv Med Oncol (2013) 0.78
Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Manag (2015) 0.77
Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection. Front Microbiol (2015) 0.76
Novel targeted therapies for the treatment of metastatic melanoma. Ochsner J (2010) 0.75
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biol (2017) 0.75
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Med (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell (2005) 7.65
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Maximizing mouse cancer models. Nat Rev Cancer (2007) 5.38
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res (2007) 4.95
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
The pancreas cancer microenvironment. Clin Cancer Res (2012) 4.10
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
Breast and ovarian cancer. N Engl J Med (2003) 3.84
Stromal biology and therapy in pancreatic cancer. Gut (2010) 3.80
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst (2002) 3.65
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst (2007) 3.25
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol (2002) 3.25
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res (2006) 3.21
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2012) 3.13
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol (2005) 3.12
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell (2009) 2.82
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res (2005) 2.76
High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res (2005) 2.72
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
A comparison of DNA copy number profiling platforms. Cancer Res (2007) 2.63
SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J Clin Invest (2011) 2.60
Gene expression patterns in ovarian carcinomas. Mol Biol Cell (2003) 2.55
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res (2006) 2.48
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41
Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell (2007) 2.36
A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35